Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29827751 | 1.00 | CYP3A4 (0.62) | CYP3A4ALDH1A1SMN1; SMN2TAAR1SLC6A2 | |
| SCHEMBL217047 | 1.00 | CYP3A4 (0.62) | CYP3A4ALDH1A1SMN1; SMN2TAAR1SLC6A2 | |
| Hydrochloric Acid SCHEMBL31545549 | 0.99 | CYP3A4 (0.61) | CYP3A4ALDH1A1SMN1; SMN2TAAR1SLC6A2 | |
| SCHEMBL31166209 | 0.88 | ALDH1A1 (0.48) | CYP3A4ALDH1A1SMN1; SMN2TAAR1SLC6A2 | |
| SCHEMBL5305466 | 0.88 | ALDH1A1 (0.48) | CYP3A4ALDH1A1SMN1; SMN2TAAR1SLC6A2 | |
| Tenamfetamine SCHEMBL9102083 | 0.83 | TAAR1 (0.57) | CYP3A4ALDH1A1SMN1; SMN2TAAR1SLC6A2 | |
| SCHEMBL2350405 | 0.83 | CYP3A4 (0.59) | CYP3A4ALDH1A1SMN1; SMN2TAAR1SLC6A2 | |
| SCHEMBL29827277 | 0.83 | CYP3A4 (0.59) | CYP3A4ALDH1A1SMN1; SMN2TAAR1SLC6A2 | |
| SCHEMBL9781426 | 0.81 | CYP3A4 (0.69) | CYP3A4ALDH1A1SMN1; SMN2MEN1KMT2A | |
| Tenamfetamine SCHEMBL9102090 | 0.80 | SLC6A4 (0.53) | CYP3A4ALDH1A1SMN1; SMN2TAAR1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4346788-A2 | ENANTIOMERIC ENTACTOGEN COMPOSITIONS AND METHODS OF THEIR USE | Arcadia Medicine, Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| WO-2022256720-A2 | ENANTIOMERIC ENTACTOGEN COMPOSITIONS AND METHODS OF THEIR USE | ARCADIA MEDICINE, INC. (US) | 2022-12-08 | — | — | WO | claimed |
| EP-4061359-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | Turtle Bear Holdings, LLC (US) | 2022-09-28 | — | — | EP | claimed |
| WO-2021101926-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | STAMETS PAUL EDWARD (US) | 2021-05-27 | — | — | WO | claimed |
| US-20210145851-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS, LLC | 2021-05-20 | — | — | US | claimed |
| US-20210069170-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS, LLC | 2021-03-11 | — | — | US | claimed |
| US-9435816-B2 | Deuterium free, stable isotope labeled 2-phenylethylamine hallucinogens and/or stimulants, methods of their preparation and their use | CHIRON AS (NO) | 2016-09-06 | — | — | US | claimed |
| WO-2014153099-A2 | METHOD FOR USING EXHALED BREATH TO DETERMINE THE PRESENCE OF DRUG | Pulmonary Analytics (US) | 2014-09-25 | — | — | WO | claimed |
| US-20140288454-A1 | Method For Using Exhaled Breath to Determine the Presence of Drug | Pulmonary Analytics (US) | 2014-09-25 | — | — | US | claimed |
| US-20140227792-A1 | DEUTERIUM FREE, STABLE ISOTOPE LABELED 2-PHENYLETHYLAMINE HALLUCINOGENS AND/OR STIMULANTS, METHODS OF THEIR PREPARATION AND THEIR USE | CHIRON A/S (NO) | 2014-08-14 | — | — | US | claimed |
| WO-2013014287-A2 | DEUTERIUM FREE, STABLE ISOTOPE LABELED 2-PHENYLETHYLAMINE HALLUCINOGENS AND/OR STIMULANTS, METHODS OF THEIR PREPARATION AND THEIR USE | CHIRON AS (NO) | 2013-01-31 | — | — | WO | claimed |
| EP-2551675-A1 | Deuterium free, stable isotope labeled 2-phenylethylamine hallucinogens and/or stimulants, methods fo their preparation and their use | Chiron AS (NO) | 2013-01-30 | — | — | EP | claimed |
| US-20050130312-A1 | Method for the detection of compounds comprising methylenedioxyphenyl and testing kit for the same | GLATTSTEIN BARUCH (IL) | 2005-06-16 | — | — | US | claimed |
| US-20020013372-A1 | Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors | PFIZER PRODUCTS INC. | 2002-01-31 | — | — | US | claimed |
| EP-1134290-A2 | Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors | Pfizer Products Inc. (US) | 2001-09-19 | — | — | EP | claimed |
| US-12630504-B2 | Phenethylamine derivatives, compositions, and methods of use | CYBIN IRL LIMITED (IE) | 2026-05-19 | — | — | US | disclosed |
| US-20260108544-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| WO-2003052426-A1 | A METHOD FOR THE DETECTION OF COMPOUNDS COMPRISING METHYLENEDIOXYPHENYL AND TESTING KIT FOR THE SAME | GLATTSTEIN ORA (IL) | 2003-06-26 | — | — | WO | disclosed |
| US-20020013372-A1 | Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors | PFIZER PRODUCTS INC. | 2002-01-31 | — | — | US | disclosed |
| EP-1134290-A2 | Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors | Pfizer Products Inc. (US) | 2001-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140227792-A1 | DEUTERIUM FREE, STABLE ISOTOPE LABELED 2-PHENYLETHYLAMINE HALLUCINOGENS AND/OR STIMULANTS, METHODS OF THEIR PREPARATION AND THEIR USE | PNMT, HTR2C, HTR2A | CYP3A4 98/4885ALDH1A1 2538/4885SMN1; SMN2 1078/4885 |
| US-20210145851-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | CYP3A4 2427/4885ALDH1A1 4132/4885SMN1; SMN2 330/4885 |
| US-12630504-B2 | Phenethylamine derivatives, compositions, and methods of use | HTR2C, HTR1A, HTR2A | CYP3A4 570/4885ALDH1A1 2351/4885SMN1; SMN2 1548/4885 |
| US-20210069170-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | CYP3A4 2427/4885ALDH1A1 4132/4885SMN1; SMN2 330/4885 |
| US-20260108544-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | CYP3A4 1901/4885ALDH1A1 2631/4885SMN1; SMN2 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.